Kineta Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.8yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO

Kineta has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Craig Philips	President & Secretary	1.8yrs	US$993.40k	0.78% $ 53.5k
Keith Baker	Chief Financial Officer	1.8yrs	US$813.69k	0.14% $ 9.5k
Thierry Guillaudeux	Chief Scientific Officer	1.8yrs	no data	0.18% $ 12.2k
Gary Gentges	Executive Vice President of Corporate Development	no data	no data	no data
Pauline Kenny	Advisor	less than a year	US$741.73k	0.15% $ 10.3k

1.8yrs

Average Tenure

56.5yo

Average Age

Experienced Management: KANT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Arkowitz	Independent Director	1.8yrs	US$141.55k	0.023% $ 1.6k
Kimberlee Drapkin	Independent Director	1.3yrs	US$69.85k	0% $ 0
Shawn P. Iadonato	Chairman of the Board	1.8yrs	US$1.28m	5.62% $ 385.6k
Raymond Bartoszek	Independent Director	1.8yrs	US$86.37k	14.68% $ 1.0m
Marion Foote	Independent Director	1.8yrs	US$90.12k	1.17% $ 80.2k
Scott Dylla	Independent Director	1.3yrs	US$66.10k	0.033% $ 2.2k
Richard Peters	Lead Independent Director	1.8yrs	US$148.18k	0.73% $ 50.4k
Lisa Coussens	Member of Scientific Advisory Board	4.4yrs	no data	no data
Patricia LoRusso	Member of Scientific Advisory Board	4.4yrs	no data	no data
Michael Curran	Member of Scientific Advisory Board	4.4yrs	no data	no data
Evan Yu	Member of Scientific Advisory Board	1.5yrs	no data	no data
Myriam Chalabi	Member of Scientific Advisory Board	1.5yrs	no data	no data

1.8yrs

Average Tenure

60yo

Average Age

Experienced Board: KANT's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Kineta Management

Management criteria checks 0/4

Key information

Recent management updates

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Board Appointments

No independent directors

Recent updates

Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index

Nasdaq Suspends Trading of Kineta's Common Stock Following Denial of Continued Listing Request, Effective September 19, 2024 and to File Form 25-NSE with the Securities and Exchange Commission

Kineta, Inc.(OTCPK:KANT) dropped from NASDAQ Composite Index

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Kineta, Inc. Re Opens Enrollment for the Vista-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Kineta Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta Receives Written Notice from Nasdaq Regarding Non-Compliance Minimum Closing Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial

Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Restructuring and Workforce Reduction

Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity

Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors

Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial

New major risk - Share price stability

Kineta Regains Compliance with Nasdaq Listing Rules

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kineta, Inc. Announces Board Appointments

Third quarter 2022 earnings released

No independent directors

Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. (NasdaqCM:YMTX) from a group of shareholders in a reverse merger transaction.

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age